Results from ARTISTRY trials will be submitted to regulatory agencies for review. Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an ...
HIV patients on a single-tablet daily regimen had better treatment retention and viral suppression than patients taking multiple pills, in a study by a Michael E. DeBakey Veterans Affairs Medical ...
FOSTER CITY, Calif., February 25, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing ...
HIV patients on a single-tablet daily regimen had better outcomes than patients taking multiple pills per day, a new study shows. HIV patients on a single-tablet daily regimen had better treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results